Stathmin, also known as oncoprotein 18 (Op18), is a ubiquitously expressed 19 kDa cytosolic phosphoprotein responsible for integrating various cellular regulatory signals. Stathmin has been implicated in both G1-S and G2-M checkpoint control of cell cycle progression and plays a major role in cell proliferation, differentiation, development and morphogenesis. Overexpression of Stathmin has been associated with tumor progression in endometrial carcinomas, ovarian carcinoma and oral squamous cell carcinoma. A recent study by Howitt et al. on 193 cervical lesions demonstrated that Stathmin was positive in 5/56 (9%) CIN1, 5/11 (45%) CIN2, 14/15 (93%) CIN3 cases of cervical intraepithelial neoplasias; and all of adenocarcinoma in situ (19/19), invasive squamous cell carcinoma (32/32) and adenocarcinoma (34/34) cases. It is valuable to distinguish CIN3 from the majority of low-grade precursors and negative/reactive cervical biopsies.